Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Maruko, Ichiro; Iida, Tomohiro; Sugano, Yukinori; Saito, Masaaki; Sekiryu, Tetsuju

doi:10.1016/j.ajo.2010.10.030

Cited by 127 publications

(75 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Recent researchers adopted enhanced depth imaging OCT in PCV examination, showing reduction of choroidal thickness after PDT application. 18 A subnormal choroidal thickness secondary to choroidal vasculature thrombosis may hinder the visual outcome. 19 Hence, PDT is seemingly not desirable for multiple recurrence cases.…”

Section: Discussionmentioning

confidence: 99%

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Young

et al. 2014

Eye

View full text Add to dashboard Cite

Aim To report the visual outcome of polypoidal choroidal vasculopathy receiving combined treatment with photodynamic therapy using Visudyne and intravitreal ranibizumab injections, and to analyze the predictive factors of visual outcome at 1 year post treatment. Methods Seventy-four consecutive patients with newly diagnosed polypoidal choroidal vasculopathy were treated with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab. The final visual outcome and polyp eradication rate at 1 year were reported. A stepwise regression model was used to estimate the baseline clinical factors predictive of better visual outcome and polyp eradication.Results Visual acuities at 12-months followup improved significantly compared with baseline from 0.828 logMAR to 0.728 logMAR (P ¼ 0.026). The mean foveal thickness decreased from 380±175 to 278±117 mm. In all 29.7% of eyes improved at least by 0.3 logMAR, and 55.4% remained stable in visual acuity with less than 0.3 logMAR change. Overall, 85% of eyes achieved at least stable vision, 20.2% (15/74) cases achieved polyp eradication on angiogram, and 60.8% (45/74) achieved polyp size reduction on angiogram at 1 year. Regarding predictive factors, the baseline visual acuity (P ¼ 0.003), no foveal involvement by abnormal choroidal vasculature (Po0.0001), absence of hard exudates (0.001) or subretinal fluid (o0.0001) are important clinical factors affecting the final visual outcome. Conclusions Combination therapy with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab injections resulted in 85% success rate on visual stabilization and 81% success rate in polypoidal lesion control.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Young

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…Further, certain reports noted changes in subfoveal choroidal thickness after treatment. 4,7,[11][12][13][14] Because macular edema in patients with CRVO appears to be closely related to vascular endothelial growth factor (VEGF) levels in the vitreous, 15,16 inhibiting VEGF appears to be a reasonable therapeutic approach. [17][18][19] Although many studies have reported that central macular thickness in CRVO decreases after anti-VEGF treatment, such as intravitreal bevacizumab therapy, we could find no reports of changes in choroidal thickness in CRVO patients after treatment.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Central Retinal Vein Occlusion

Tsuiki

Suzuma

Ueki

et al. 2013

American Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE: To evaluate subfoveal choroidal thickness in patients with central retinal vein occlusion (CRVO) using enhanced depth imaging (EDI) optical coherence tomography (OCT). DESIGN: Retrospective observational study.METHODS: We measured bilateral subfoveal choroidal thickness, averaged for 100 scans, in 36 patients (mean age, 66 ± 15 years; 26 women and 10 men) with unilateral CRVO by using the EDI modes of the Spectralis OCT system. Twenty-two patients were treated with intravitreal bevacizumab (1.25 mg/0.05 mL), and subfoveal choroidal thickness was measured before and after treatment. Statistical analysis was performed to compare subfoveal choroidal thickness of CRVO and fellow eyes, and subfoveal choroidal thickness before and after intravitreal bevacizumab.RESULTS: Mean subfoveal choroidal thickness measured in 36 eligible eyes of 36 patients was 257.1 ± 83.2 μm, which was significantly greater than that in fellow eyes (222.6 ± 67.8 μm) (P < .01, paired t-test). There was strong correlation between CRVO eyes and fellow eyes (r = .79, P < .01). Mean subfoveal choroidal thickness after intravitreal bevacizumab was 227.7 ± 65.1 μm, which was significantly thinner than that before intravitreal bevacizumab Abstract (MUST be submitted as a separate file) therapy (266.9 ± 79.0 μm) (P < .01, paired t-test).CONCLUSIONS: Subfoveal choroidal thickness of CRVO eyes was significantly greater than that of fellow eyes and significantly decreased after intravitreal bevacizumab treatment. EDI-OCT can be used to evaluate choroidal involvement in CRVO and may assist noninvasive diagnosis and management of this disease.

show abstract

“…In particular, a thin choroid in eyes with exudative and nonexudative age-related macular degeneration (AMD) 2,3 and a thick choroid in eyes with polypoidal choroidal vasculopathy (PCV) [2][3][4] and central serous chorioretinopathy (CSC) 5,6 were notable findings that broadened the understanding of the role of the choroid in the development of these disorders.…”

Section: Introductionmentioning

confidence: 99%

Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy

Kim

Kang

Kim

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate the variability in subfoveal choroidal thickness measurements in patients with age-related macular degeneration (AMD) and central serous chorioretinopathy using enhanced depth imaging optical coherence tomography (EDI-OCT). Methods One hundred and sixty eyes of 160 patients who were diagnosed with early AMD (N ¼ 40), exudative AMD (N ¼ 40), polypoidal choroidal vasculopathy (PCV, N ¼ 40), or central serous chorioretinopathy (CSC, N ¼ 40) were included in this retrospective observational study. In addition, we included 40 normal eyes of 40 subjects. Subfoveal choroidal thickness was measured manually by two masked observers based on EDI-OCT images. The correlation of choroidal thickness with the absolute value of the difference in the choroidal thickness measurement was estimated for all 200 eyes. Intraobserver and interobserver coefficients of repeatability (CRs) were calculated. Results There was a significant positive correlation between subfoveal choroidal thickness and both intraobserver (Po0.001) and interobserver (Po0.001) difference in choroidal thickness measurements. The mean intraobserver CRs in nonexudative AMD, exudative AMD, PCV, CSC, and normal eyes were B15-21, 23-29, 24-35, 32-38, and 19-25 mm, respectively. The mean interobserver CRs were B24-28, 30-36, 39-45, 46-57, and 26-35 mm, respectively. Conclusions Relatively great measurement variability should be considered when investigating eyes with pathologic conditions related to a thick choroid, including PCV or CSC.

show abstract

Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Cited by 127 publications

References 43 publications

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Central Retinal Vein Occlusion

Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy

Contact Info

Product

Resources

About